The human brain is complex to the extent its internal wiring mechanism is least understood. Imbalances cause problems with health, but knowing about serotonin receptors has improved our understanding of control mechanisms involving cognitive emotion, memory, and sleep-wake cycle. Bright Minds team of scientists seeks to create the next generation of serotonin drugs to target specific conditions, reducing side effects and improving therapeutic action, helping patients lead a better life.
Questions Related to the Use of Psychedelic Drugs
The creation of novel chemical entities to improve first-generation psychedelic compounds like psilocybin to make specific drugs that target serotonin receptors help influence a specific neural circuit. This is not possible with other currently approved drugs such as selective serotonin reuptake inhibitors. The questions that arise to the mind are these:
1) Will psychedelic drugs be a game-changer during these COVID-19 times when mental illness is on the rise?
2) Can we use magic mushrooms for addiction, depression, and ailments such as epilepsy?
3) How safe is it for older adults to use second-generation psychedelic drugs?
4) After terminally ill patients could legally consume psychedelic drugs to treat end-of-life distress, will it become a main-stream medical treatment?
Currently approved drugs show side effects because they are not specific to a particular receptor type. Also, the patients do not respond well to the treatment.
Controlling Disease Through The Receptor Circuit
Serotonin receptors co-localize with GABAergic, cholinergic, and glutamatergic neurons helping serotonin receptor agonists influence the major neurotransmitter systems. They can influence the progress of disease a lot. The Bright Minds Bio team has engineered superior molecules with improvements to the current state of the existence of molecules that improve targeting specific serotonin receptors in the brain.
The Action of Serotonin Receptors
The team comprises top scientists with at least 25 years of experience in drug development. Patients with chronic pain suffer because of insufficient control of the functional connectivity of brain circuits. Existing approved medications solve little. The key action on the 5-HA2A serotonin receptor helps solve major depressive disorder symptoms. But Psilocybin has a potent effect on 5-HA2A/C and 5-HA2C serotonin receptors.
Use Effective Medicine Through Targeting
There are 14 distinct subtypes of Serotonin (5-HT) receptors distributed throughout the central nervous system, including the spinal cord. Drug development based on translational science has helped us develop an extensive library of proprietary medicine to target 5-HA2A, 5-HA2A/C, and 5-HA2C serotonin receptors. Because of the important role 5-HA2C plays in impulse control, the team is developing compounds that will help the treatment of binge eating disorders, smoking, cocaine abuse, and opiate abuse. We target patients with major depressive disorder (MDD) resistant to SSRIs who need electric shock treatment or nasal ketamine treatment with Biosciences drugs without side effects like worsening impulsivity, weight gain, or worsening sleep. Atypical antipsychotics used to treat HIDA symptoms have a modest effect.
Opt For Dependable Treatment Methods
Precision is the key, and intelligent drug design based on advanced molecular modeling helps the team select compounds showing the best activity profile. You can avoid the use of unapproved psychedelic drugs and opiates to treat pain. We have made it possible to treat a wide range of disorders helping patients lead a healthy life.